Introduction
============

During the past decade, oral sampling has gained increased attention as an alternative to plasma in monitoring immunity in epidemiological studies. Oral sampling has a number of advantages when compared to venipuncture, including the fact that sampling is simple, non-invasive, painless, and allows for self-collection (Wade and Haegele, [@B16]; Kirschbaum and Hellhammer, [@B4]). Many biomarkers have been evaluated in oral secretions including hormones (Riad-Fahmy et al., [@B10]; Wade and Haegele, [@B16]), vaccine-induced antibodies (Kozlowski et al., [@B5]; Rowhani-Rahbar et al., [@B11]), and cytokines (Streckfus et al., [@B14]). This makes oral secretions a relevant source for monitoring hormone levels and antibody responses in vaccinated individuals. We were interested in determining whether oral immunoglobulin (Ig) levels represent a good surrogate for cervical mucosal Ig levels. This is of particular relevance for monitoring recipients of the recently licensed prophylactic HPV vaccines (Muñoz et al., [@B6]; Paavonen et al., [@B9]). The new HPV vaccines induce a strong antibody response that is believed to be responsible for the protection against vaccine-related type infections. Because vaccination is administered systemically whereas protection occurs locally at the genital tract mucosa, we have had an interest in better understanding the patterns of both systemic and local immune responses and their interrelationship.

We and others have shown that Ig levels in cervical secretions may be hormonally influenced, as reflected by fluctuations in cervical IgG and IgA during the menstrual cycle, with levels being lowest around ovulation and higher in the follicular and luteal phases of the cycle (Nardelli-Haefliger et al., [@B7]; Safaeian et al., [@B12]). In contrast, systemic Ig levels have been shown not to be affected by the menstrual cycle and do not correlate with cervical Ig levels (Safaeian et al., [@B13]).

It is still unknown whether oral levels of Ig reflect those at the cervix. To determine whether oral secretions can be used as an alternative to cervical secretions to monitor local Ig levels, we examined (1) the association between oral and cervical Ig (both IgG and IgA) levels, and (2) the determinants of total oral IgG and IgA levels to see whether they are similar to those observed at the cervix.

Materials and Methods
=====================

Population
----------

To evaluate mucosal and systemic levels of total IgG and IgA over the menstrual cycle, a subset of young adult women from Costa Rica who were participants in a NCI-sponsored study designed to examine the natural history of HPV infection and cervical intraepithelial neoplasia (Herrero et al., [@B2]) were contacted if they were 25--35 years old, had no evidence of high-grade cervical lesions, were not pregnant, and had an intact uterus. The details of this study have been described previously (Safaeian et al., [@B12]). In brief, a total of 202 women were invited to participate and asked to agree to an interview and the collection of cervical and oral secretions (blood was also collected and results reported previously; Safaeian et al., [@B13]) at three time points during one menstrual cycle within the following time frames: visit 1 (follicular phase) 5--8 days after cycle onset, visit 2 (periovulatory phase) 14--16 days after cycle onset, and visit 3 (luteal phase) 19--22 days after cycle onset. After excluding women who were pregnant (*n* = 3), currently breast-feeding (*n* = 17), or had menstrual cycles that were either too short (\<25 days) or too long (\>36 days; *n* = 28), we selected for study a subset of 104 women, 20 of whom were oral contraceptive users (the remaining were naturally cycling). For the present analysis, we further excluded women who did not provide specimens at all three visits (*n* = 1), whose oral sponge weight was unusually low (lower than the mean weight of dry sponges; *n* = 4), whose cervical sponge weight was unusually low (*n* = 13), and whose cervical IgG and IgA levels were considered to be outliers (*n* = 1). A total of 85 women were included in the final analysis. All participants signed an informed consent, and the study was approved by the ethical committees at the National Cancer Institute, USA and INCIENSA, Costa Rica.

Sample collection and extraction
--------------------------------

Oral samples were collected using the cellulose-based Ultracell sponges by holding a sponge on the inner cheek for 15 s and turning it over to collect oral secretions for another 15 s on the opposite cheek. Collection of cervical secretions has been described previously (Kemp et al., [@B3]; Safaeian et al., [@B12]). Following collection, the sponges (both oral and cervical) were immediately stored in liquid nitrogen. The secretions were extracted from Ultracell sponges according to the following protocol. Three hundred microliter of extraction buffer (PBS, Invitrogen, Grand Island, NY, USA; 1.5% NaCl, Sigma-Aldrich, St. Louis, MO, USA; 100 μg/ml Aprotinin, Sigma-Aldrich; 150 ng/ml mouse IgG1, extraction control, BD Biosciences, San Jose, CA, USA) was added to the top of each sponge. The sponges were incubated at 4°C for 30 min prior to centrifugation at 13,000 × *g* for 15 min at 4°C. An additional 300 μl of extraction buffer (sans extraction control) was added to each sponge and immediately centrifuged. Prior to adding 4 μl of fetal calf serum for storage, 20 μl of extract was saved for protein analysis, and 5 μl was tested for presence of hemoglobin (Hemastix, Bayer, Elkhart, IN, USA).

Determination of immunoglobulin levels
--------------------------------------

Total human IgG, human IgA, and extraction control (mouse IgG1) were measured in duplicate using an ELISA according to the manufacturer's protocol (Bethyl Laboratories, Montgomery, TX, USA). In order to account for variations in the amount of oral secretion collected between participants, the antibody levels were standardized based on the following formula: \[specimen weight (g) − mean dry sponge weight (g) + 0.6 (g)\]/\[specimen weight (g) − mean dry sponge weight\]; 0.6 (g) refers to the weight of the extraction buffer added to each specimen. Furthermore, we added a standardized amount of mouse IgG1 to the extraction buffer in order to monitor extraction efficiency. The median percent recovery was 75.5% (IQR: 62.7--87.1%). Results from analyses that evaluated standardized oral Ig levels corrected for percent recovery did not differ from those obtained using the uncorrected standardized oral Ig levels except for the correlation between oral IgA levels amongst smoking status \[linear regression coefficient (LRC) 0.47; 95% CI (0.02--0.92); *p* = 0.04; data not shown\].

Statistical analyses
--------------------

The IgG and IgA levels were normalized by log transformation. Geometric mean titers (GMT) of oral IgG and IgA were computed and reported by categories of the covariates examined. Our main objective was to examine the association of oral IgG and IgA levels with cervical IgG and IgA, respectively. Other variables considered as potential confounders were: menstrual cycle phase (follicular, periovulatory, and luteal), oral contraceptive use (current versus not), age (25--29, 30--32, and 33--35 years), smoking (current versus not), cervical HPV infection (current versus not), acute illness (current versus not), parity (0, 1--3, and ≥4), saliva sponge weight (\<0.21 versus \>0.21 g), and presence of hemoglobin (negative, trace, and positive). The Kruskal--Wallis test was used to assess significant changes in oral IgG and IgA levels during the three menstrual cycle phases. Because we had three observations for each participant, we applied generalized estimating equations (GEE) models for correlated data to determine which factors were associated with oral IgG and IgA levels. Robust methods for linear regression with unstructured correlation structure were used to estimate standard errors and coefficients adjusted for multiple observations for each participant. A *p* \< 0.05 is considered significant. LRC and associated 95% confidence intervals (CI) are presented. Analysis was performed with STATA 9.2 (StataCorp LP, College Station, TX, USA), SAS 9.3, and JMP 7 statistical programs (SAS Institute Inc., Cary, NC, USA).

Results
=======

A total of 85 women were included in this analysis. Each woman was sampled at three time points during a single menstrual cycle for a total of 255 oral samples with matching cervical samples. The overall geometric mean concentration of oral IgG and IgA from the 255 samples was 19.6 and 101 μg/ml, respectively. The levels of total IgG in oral samples were 30-fold lower than the IgG levels found in the cervix (GMT for cervical IgG = 567 μg/ml), and the levels of IgA in oral samples were 2.5-fold lower than the levels of IgA detected in the cervix (GMT for cervical IgA = 269 μg/ml). Oral IgG levels were significantly associated with oral IgA levels from the 255 samples considered as a whole (LRC: 1.82; 95% CI, 1.70--1.96; Figure [1](#F1){ref-type="fig"}).

![**Association of oral IgG to oral IgA levels**. Oral samples collected from the three phases of the menstrual cycle from 85 participants were measured for IgG and IgA levels. The graph represents a scatter plot of untransformed levels of oral IgG and IgA from all three phases of the menstrual cycle from each participant, and a *p*-value \<0.05 was considered significant. LRC, Linear Regression Coefficient.](fonc-02-00061-g001){#F1}

Because, we previously reported that cervical levels of IgG and IgA were significantly lower during the periovulatory phase of the menstrual cycle among naturally cycling women (Safaeian et al., [@B12]), we examined whether the menstrual cycle affected oral IgG and IgA levels. In contrast to what we reported previously at the cervix, we observed no significant change in oral levels of IgG (*p* = 0.1) or IgA (*p* = 0.2) between phase of menstrual cycle (Figure [2](#F2){ref-type="fig"}). This was true overall (Figure [2](#F2){ref-type="fig"}A) and in analysis stratified by oral contraceptive use (Figures [2](#F2){ref-type="fig"}B,C).

![**Distribution of oral IgG and IgA levels during the three phases (follicular, periovulatory, and luteal) of the menstrual cycle overall (A) and stratified by oral contraceptive (OC) use (B,C)**. The levels of IgG and IgA presented in the graphs is based on untransformed values. The *p*-value is calculated based on Kruskal--Wallis test, and a *p*-value \<0.05 is considered significant. GMT, Geometric mean (μg/ml).](fonc-02-00061-g002){#F2}

Figure [3](#F3){ref-type="fig"}A depicts the association between oral IgG and cervical IgG from the 255 samples considered as a whole regardless of the phase of the menstrual cycle. Oral IgG levels were not associated with cervical IgG levels (LRC: 0.01; 95% CI, −0.05 to 0.07). Similarly as depicted in Figure [3](#F3){ref-type="fig"}B, oral IgA levels were not associated with cervical IgA levels (LRC: 0.02; 95% CI, −0.04 to 0.08).

![**Comparison of IgG and IgA levels between oral and cervical specimens**. Matching oral and cervical secretion samples from the three phases of the menstrual cycle from 85 participants were measured for IgG and IgA levels. The scatter plots of oral-cervix IgG **(A)** and IgA **(B)** levels are plotted based on untransformed values and include the three phases of the menstrual cycle from each participant. A *p*-value \<0.05 was considered significant, and LRC stands for Linear Regression Coefficient.](fonc-02-00061-g003){#F3}

When other potential determinants of oral IgG and IgA levels were evaluated (Table [1](#T1){ref-type="table"}), only sponge weight was significantly associated with oral IgG (LCR: −0.72, 95% CI, −0.86 to −0.59) and oral IgA levels (LCR: −0.54; 95% CI, −0.66 to −0.42). Although not statistically significant, we did observe that oral IgG and IgA levels were elevated in specimens which hemoglobin was detectable by our Hemastix strip test (Table [1](#T1){ref-type="table"}).

###### 

**Association between covariates of interest and oral IgG and IgA (μg/ml) levels**.

                                                     IgG (μg/ml)   IgG                                                      IgA (μg/ml)   IgA
  -------------------------------------------- ----- ------------- -------------------------------------------------------- ------------- -------------------------------------------------------
  Oral Ig[^d^](#tfn4){ref-type="table-fn"}     255   19.6                                                                   101.3         
  Cervix Ig[^d^](#tfn4){ref-type="table-fn"}   255   566.7         0.01 (−0.05 to 0.07)                                     268.6         0.02 (−0.04 to 0.08)
  Plasma Ig[^d^](#tfn4){ref-type="table-fn"}   255   8204.5        **0.74 (0.12 to 1.35)**                                  2030.1        −0.03 (−0.32 to 0.25)
  **AGE**                                                                                                                                 
  27--30                                       84    22            −0.05 (−0.11 to 0.01)[^c^](#tfn3){ref-type="table-fn"}   98.5          0.01 (−0.04 to 0.06)[^c^](#tfn3){ref-type="table-fn"}
  31--33                                       96    19.4                                                                   101.0         
  34--35                                       75    17.4                                                                   105.0         
  **ORAL COLLECTION SPONGE WEIGHT**                                                                                                       
  \>0.21 g                                     130   12.9          Reference                                                74.9          Reference
  \<0.21 g                                     125   30.1          −**0.72 (−0.86 to −0.59)**                               138.6         −**0.54 (−0.66 to −0.42)**
  **HEMOGLOBIN IN ORAL SECRETIONS**                                                                                                       
  Negative                                     21    17.2          Reference                                                95.6          Reference
  Trace                                        184   17.3          −0.09 (−0.44 to 0.26)                                    97.2          −0.04 (−0.34 to 0.26)
  Positive                                     50    32.2          0.23 (−0.17 to 0.62)                                     120.7         0.10 (−0.23 to 0.43)
  **CURRENT OC USE**                                                                                                                      
  No                                           191   19.3          Reference                                                98.6          Reference
  Yes                                          44    18.0          0.01 (−0.31 to 0.34)                                     104.2         0.06 (−0.2 to 0.32)
  **HPV INFECTION**                                                                                                                       
  No                                           207   19.5          Reference                                                102.1         Reference
  Yes                                          42    18.5          −0.05 (−0.44 to 0.34)                                    95.1          −0.08 (−0.38 to 0.23)
  **PARITY**                                                                                                                              
  0                                            30    19.8          Reference                                                124.4         Reference
  1--3                                         162   17.5          −0.12 (−0.57 to 0.33)                                    91.6          −0.30 (−0.65 to 0.04)
  ≥4                                           63    25.7          0.27 (−0.23 to 0.77)                                     119.1         −0.04 (−0.43 to 0.35)
  **CURRENT ILLNESS**                                                                                                                     
  No                                           174   19.9          Reference                                                101.6         Reference
  Yes                                          81    18.9          −0.02 (−0.19 to 0.15)                                    100.6         0.02 (−0.13 to 0.16)
  **CURRENT SMOKER**                                                                                                                      
  No                                           228   19.1          Reference                                                97.6          Reference
  Yes                                          27    23.5          0.22 (−0.25 to 0.69)                                     139.1         0.35 (−0.01 to 0.72)

*^a^Geometric mean values of IgG and IgA are based on log transformed values which have been transformed back to the original measurements*.

*^b^The Generalized Estimation Equation (GEE) model was used to evaluate the associations between the listed covariates and log transformed oral IgG and IgA values. The Linear Regression Coefficient (LRC) values are presented along with 95% CIs*.

*^c^Age entered as a continuous variable in the model*.

*^d^The immunoglobulin measures presented reflect the geometric mean of all samples regardless of the menstrual cycle*.

*Bold text represents an LRC being significant at *p* \< 0.05*.

Discussion
==========

Saliva represents a potential alternative sample collection method for immune monitoring studies. This could simplify efforts to monitor the long-term immunological impact of vaccines such as the recently approved prophylactic HPV vaccines. However, it is still unknown whether saliva levels of antibodies reflect local levels at the cervix. In this study, we evaluated whether total oral Ig measures were good proxies for genital tract Ig levels. The aims were to (1) directly compare Ig levels measured in the oral cavity against those measured at the cervix and (2) examine whether factors previously found to affect levels of Ig at the cervix were also associated with oral Ig levels.

We showed that IgG and IgA in oral secretions are lower than levels found in the cervix and not reflective of IgG or IgA levels in the cervix. The overall levels of oral IgG and IgA reported here are in agreement with other studies (Norhagen et al., [@B8]; Tamashiro and Constantine, [@B15]; Engstrom et al., [@B1]; Kozlowski et al., [@B5]), and the levels of oral IgG and IgA suggest that the collection device in our study absorbed whole saliva, which consists of all oral mucosa products. Furthermore, these results suggest that our collection and storage method preserved immunoglobulins even though oral fluid contains enzymes capable of degrading proteins such as immunoglobulins.

We examined the association of oral IgG and IgA with menstrual cycle and hormonal contraceptive use. Oral IgG and IgA levels were not affected by phase of menstrual cycle or by oral contraceptive use. These observations, while consistent with previously reported findings for plasma levels (Safaeian et al., [@B13]), contrast with the reported strong effect of menstrual cycle and oral contraceptive use on cervical Ig levels (Safaeian et al., [@B12]), further reinforcing the need for caution when using oral Ig measurements to reflect levels at the cervix. Although our study did not directly measure antigen-specific vaccine-induced antibody levels, our results suggest caution in using oral specimens to monitor long-term impact of vaccination programs such as the recently approved HPV vaccine.

The only statistically significant correlate of oral IgG and IgA we identified was oral sponge collection weight. The increased IgG and IgA levels among lighter weight sponges suggests that the calculated dilution factor may artificially increase the concentration of oral IgG and IgA when low levels of fluid are obtained.

Previous studies have shown that there was modest to high correlation between cervical and plasma anti-HPV16 levels (Nardelli-Haefliger et al., [@B7]; Kemp et al., [@B3]); however, this was shown to be the case among individuals who received the HPV vaccine only when menstrual cycle fluctuations were controlled by oral contraceptive use (Nardelli-Haefliger et al., [@B7]). Although antigen-specific responses have been reported to be detected in oral fluid from vaccine recipients (Rowhani-Rahbar et al., [@B11]), it is still unclear whether such responses would correlate with levels observed at the cervix among naturally cycling women.

In conclusion, our data suggest that oral IgG and IgA are not a good surrogate for total IgG and IgA measures in cervical secretions. Future studies will need to assess whether antigen-specific antibody responses in oral samples obtained from vaccinees may better reflect levels observed in cervix before such markers can be used as an alternative to cervical secretion measures when monitoring local antigen-specific humoral responses.
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